Tamsulosin modified release and oral controlled absorption system in the management of lower urinary tract symptoms suggestive of benign prostatic hyperplasia

Bibliography

• Berry SJ, Coffey DS, Walsh PC, Ewing LJ. The development of human benign prostatic hyperplasia with age. J Urol 1984;132:474-9
   PubMed Web of Science ®Google Scholar
• Price D. Potential mechanisms of action of superselective alpha(1)-adrenoceptor antagonists. Eur Urol 2001;40(Suppl 4):5-11
   PubMed Web of Science ®Google Scholar
• Artibani W. Introduction. Eur Urol 2001;40(Suppl 4):1-4
   PubMedGoogle Scholar
• Abrams P, Cardozo L, Fall M, et al. The standardisation of terminology in lower urinary tract function: report from the standardisation sub-committee of the International Continence Society. Urology 2003;61:37-49
   PubMed Web of Science ®Google Scholar
• McVary KT. BPH: epidemiology and comorbidities. Am J Manag Care 2006;12:S122-8
   PubMed Web of Science ®Google Scholar
• Madersbacher S, Alivizatos G, Nordling J, et al. EAU 2004 guidelines on assessment, therapy and follow-up of men with lower urinary tract symptoms suggestive of benign prostatic obstruction (BPH guidelines). Eur Urol 2004;46:547-54
   PubMed Web of Science ®Google Scholar
• AUA Practice Guidelines Committee. AUA guideline on management of benign prostatic hyperplasia (2003). Chapter 1. Diagnosis and treatment recommendations. J Urol 2003;170:530-47
   PubMed Web of Science ®Google Scholar
• Djavan B, Chapple C, Milani S, Marberger M. State of the art on the efficacy and tolerability of alpha1-adrenoceptor antagonists in patients with lower urinary tract symptoms suggestive of benign prostatic hyperplasia. Urology 2004;64:1081-8
   PubMed Web of Science ®Google Scholar
• van Dijk MM, de la Rosette JJMCH, Michel MC. Tamsulosin – modified-release and oral-controlled absorption system formulations in the treatment of benign prostatic hyperplasia. Therapy 2006;3:237-46
   Google Scholar
• Rudner XL, Berkowitz DE, Booth JV, et al. Subtype specific regulation of human vascular a1-adrenergic receptors by vessel bed and age. Circulation 1999;100:2336-43
   PubMed Web of Science ®Google Scholar
• Foglar R, Shibata K, Horie K, et al. Use of recombinant a1-adrenoceptors to characterize subtype selectivity of drugs for the treatment of prostatic hypertrophy. Eur J Pharmacol 1995;288:201-7
   PubMed Web of Science ®Google Scholar
• Michel MC, Grubbel B, Taguchi K, et al. Drugs for treatment of benign prostatic hyperplasia: affinity comparison at cloned alpha 1-adrenoceptor subtypes and in human prostate. J Auton Pharmacol 1996;16:21-8
   PubMedGoogle Scholar
• Yamada S, Suzuki M, Tanaka C, et al. Comparative study on alpha 1-adrenoceptor antagonist binding in human prostate and aorta. Clin Exp Pharmacol Physiol 1994;21:405-11
   PubMed Web of Science ®Google Scholar
• Davis BJ, Noble AJ, Chapple CR, Chess-Williams R. Human prostate-artery selectivity of tamsulosin, doxazosin and alfuzosin. Br J Pharmacol 2000;129(Suppl):52P
   Google Scholar
• Korstanje C, De Wijn S, Van Den Berg S, Swart P. Selective retention of tamsulosin in prostate and bladder & uroselectivity in rat as compared to dog. J Urol 2002;167(Suppl 4):218
   PubMedGoogle Scholar
• Sato S, Ohtake A, Matsushima H, et al. Pharmacological effect of tamsulosin in relation to dog plasma and tissue concentrations: prostatic and urethral retention possibly contributes to uroselectivity of tamsulosin. J Pharmacol Exp Ther 2001;296:697-703
   PubMed Web of Science ®Google Scholar
• van Hoogdalem EJ, Soeishi Y, Matsushima H, Higuchi S. Disposition of the selective alpha1A-adrenoceptor antagonist tamsulosin in humans: comparison with data from interspecies scaling. J Pharm Sci 1997;86:1156-61
   PubMed Web of Science ®Google Scholar
• Astellas Europe. Summary of product characteristics (SmPC): tamsulosin modified release (MR) 0.4 mg. Astellas Europe; 2007
   Google Scholar
• Lyseng-Williamson KA, Jarvis B, Wagstaff AJ. Tamsulosin: an update of its role in the management of lower urinary tract symptoms. Drugs 2002;62:135-67
   PubMed Web of Science ®Google Scholar
• Michel MC, Korstanje C, Krauwinkel W, Kuipers M. The pharmacokinetic profile of tamsulosin oral controlled absorption system (OCAS®). Eur Urol Suppl 2005;4:15-24
   Web of Science ®Google Scholar
• Djavan B, Milani S, Davies J, Bolodeoku J. The impact of tamsulosin oral controlled absorption system (OCAS) on nocturia and the quality of sleep: preliminary results of a pilot study. Eur Urol Suppl 2005;4:61-8
   Web of Science ®Google Scholar
• Astellas Europe. Summary of product characteristics (SmPC) tamsulosin oral controlled absorption system (OCAS) 0.4 mg. Astellas Europe; 2007
   Google Scholar
• Dunn CJ, Matheson A, Faulds DM. Tamsulosin: a review of its pharmacology and therapeutic efficacy in the management of lower urinary tract symptoms. Drugs Aging 2002;19:135-61
   PubMed Web of Science ®Google Scholar
• Abrams P, Speakman M, Stott M, et al. A dose-ranging study of the efficacy and safety of tamsulosin, the first prostate-selective alpha 1A-adrenoceptor antagonist, in patients with benign prostatic obstruction (symptomatic benign prostatic hyperplasia). Br J Urol 1997;80:587-96
   PubMedGoogle Scholar
• Abrams P, Schulman CC, Vaage S. Tamsulosin, a selective alpha 1c-adrenoceptor antagonist: a randomized, controlled trial in patients with benign prostatic ‘obstruction’ (symptomatic BPH). The European Tamsulosin Study Group. Br J Urol 1995;76:325-36
   PubMedGoogle Scholar
• Chapple CR, Wyndaele JJ, Nordling J, et al. Tamsulosin, the first prostate-selective alpha 1A-adrenoceptor antagonist. A meta-analysis of two randomized, placebo-controlled, multicentre studies in patients with benign prostatic obstruction (symptomatic BPH). European Tamsulosin Study Group. Eur Urol 1996;29:155-67
   PubMed Web of Science ®Google Scholar
• Lepor H. Phase III multicenter placebo-controlled study of tamsulosin in benign prostatic hyperplasia. Tamsulosin Investigator Group. Urology 1998;51:892-900
   PubMed Web of Science ®Google Scholar
• Narayan P, Tewari A. A second phase III multicenter placebo controlled study of 2 dosages of modified release tamsulosin in patients with symptoms of benign prostatic hyperplasia. United States 93-01 Study Group. J Urol 1998;160:1701-6
   PubMed Web of Science ®Google Scholar
• Lepor H. Long-term evaluation of tamsulosin in benign prostatic hyperplasia: placebo-controlled, double-blind extension of phase III trial. Tamsulosin Investigator Group. Urology 1998;51:901-6
   PubMed Web of Science ®Google Scholar
• Narayan P, Evans CP, Moon T. Long-term safety and efficacy of tamsulosin for the treatment of lower urinary tract symptoms associated with benign prostatic hyperplasia. J Urol 2003;170:498-502
   PubMed Web of Science ®Google Scholar
• Schulman CC, Cortvriend J, Jonas U, et al. Tamsulosin, the first prostate-selective alpha 1A-adrenoceptor antagonist. Analysis of a multinational, multicentre, open-label study assessing the long-term efficacy and safety in patients with benign prostatic obstruction (symptomatic BPH). Eur Urol 1996;29:145-54
   PubMed Web of Science ®Google Scholar
• Schulman CC, Lock TM, Buzelin JM, et al. Long-term use of tamsulosin to treat lower urinary tract symptoms/benign prostatic hyperplasia. J Urol 2001;166:1358-63
   PubMed Web of Science ®Google Scholar
• Michel MC, Mehlburger L, Bressel HU, Goepel M. Comparison of tamsulosin efficacy in subgroups of patients with lower urinary tract symptoms. Prostate Cancer Prostatic Dis 1998;1:332-5
   PubMed Web of Science ®Google Scholar
• Michel MC, Mehlburger L, Bressel HU, et al. Tamsulosin treatment of 19,365 patients with lower urinary tract symptoms: does co-morbidity alter tolerability? J Urol 1998;160:784-91
   PubMed Web of Science ®Google Scholar
• Michel MC, Mehlburger L, Schumacher H, et al. Effect of diabetes on lower urinary tract symptoms in patients with benign prostatic hyperplasia. J Urol 2000;163:1725-9
   PubMed Web of Science ®Google Scholar
• Michel MC, Bressel HU, Mehlburger L, Goepel M. Tamsulosin: real life clinical experience in 19,365 patients. Eur Urol 1998;34(Suppl 2):37-45
   PubMed Web of Science ®Google Scholar
• Michel MC, Bressel HU, Goepel M, Rubben H. A 6-month large-scale study into the safety of tamsulosin. Br J Clin Pharmacol 1999;48:890P-891P
   Google Scholar
• Batista JE, Palacio A, Torrubia R, et al. Tamsulosin: effect on quality of life in 2740 patients with lower urinary tract symptoms managed in real-life practice in Spain. Arch Esp Urol 2002;55:97-105
   PubMedGoogle Scholar
• Mann RD, Biswas P, Freemantle S, et al. The pharmacovigilance of tamsulosin: event data on 12 484 patients. BJU Int 2000;85:446-50
   PubMed Web of Science ®Google Scholar
• Shakir S, Pearce G, Mann RD. Finasteride and tamsulosin used in benign prostatic hypertrophy: a review of the prescription-event monitoring data. BJU Int 2001;87:789-96
   PubMed Web of Science ®Google Scholar
• Buzelin JM, Fonteyne E, Kontturi M, et al. Comparison of tamsulosin with alfuzosin in the treatment of patients with lower urinary tract symptoms suggestive of bladder outlet obstruction (symptomatic benign prostatic hyperplasia). The European Tamsulosin Study Group. Br J Urol 1997;80:597-605
   PubMedGoogle Scholar
• Nordling J. Efficacy and safety of two doses (10 and 15 mg) of alfuzosin or tamsulosin (0.4 mg) once daily for treating symptomatic benign prostatic hyperplasia. BJU Int 2005;95:1006-12
   PubMed Web of Science ®Google Scholar
• Narayan P, O'Leary MP, Davidai G. Early efficacy of tamsulosin versus terazosin in the treatment of men with benign prostatic hyperplasia: a randomized, open-label trial. J Appl Res 2005;5:237-45
   Google Scholar
• Chapple CR, Lorenz J, Mortensen R, et al. Tamsulosin oral controlled absorption system (OCAS) in patients with lower urinary tract symptoms suggestive of benign prostatic hyperplasia (LUTS/BPH): efficacy and tolerability in a phase 2b dose-response study. Eur Urol Suppl 2005;4:25-32
   Web of Science ®Google Scholar
• Chapple CR, Al-Shukri SH, Gattegno B, et al. Tamsulosin Oral Controlled Absorption System (OCAS) in patients with lower urinary tract symptoms suggestive of benign prostatic hyperplasia (LUTS/BPH): efficacy and tolerability in a placebo and active comparator controlled phase 3a study. Eur Urol Suppl 2005;4:33-44
   Web of Science ®Google Scholar
• Narayan P, Lepor H. Long-term, open-label, phase III multicenter study of tamsulosin in benign prostatic hyperplasia. Urology 2001;57:466-70
   PubMed Web of Science ®Google Scholar
• de Mey C, Michel MC, McEwen J, Moreland T. A double-blind comparison of terazosin and tamsulosin on their differential effects on ambulatory blood pressure and nocturnal orthostatic stress testing. Eur Urol 1998;33:481-8
   PubMed Web of Science ®Google Scholar
• de Mey C, Terpstra I. Orthostatic effects of alfuzosin twice daily vs. tamsulosin once daily in the morning. J Urol 2000;163(Suppl 4):220 Abstract 378
   Google Scholar
• Barendrecht MM, Koopmans RP, de la Rosette JJ, Michel MC. Treatment of lower urinary tract symptoms suggestive of benign prostatic hyperplasia: the cardiovascular system. BJU Int 2005;95(Suppl 4):19-28
   PubMed Web of Science ®Google Scholar
• Chadha V, Borooah S, Tey A, et al. Floppy iris behaviour during cataract surgery: associations and variations. Br J Ophthalm 2007;91:40-2
   PubMed Web of Science ®Google Scholar
• Nguyen DQ, Sebastian RT, Philip J. Intraoperative floppy iris syndrome associated with tamsulosin. BJU Int 2006;97:197
   PubMedGoogle Scholar
• Michel MC, Korstanje C, Krauwinkel W, et al. Comparison of vascular a1-adrenoceptor antagonism of tamsulosin in oral controlled absorption system (OCAS) and modified release (MR) formulations. Eur Urol Suppl 2005;4:45-52
   Web of Science ®Google Scholar
• Michel MC, Korstanje C, Krauwinkel W, et al. Cardiovascular safety of the oral controlled absorption system (OCAS) formulation of tamsulosin compared to the modified release (MR) formulation. Eur Urol Suppl 2005;4:53-60
   Web of Science ®Google Scholar
• Michel MC, Chapple CR. Comparison of the cardiovascular effects of tamsulosin oral controlled absorption system (OCAS®) and alfuzosin prolonged release (XL). Eur Urol 2006;49:501-9
   PubMed Web of Science ®Google Scholar
• Bowden E, Hall S, Folly SJ, Rundle JSH. Tamsulosin in the treatment of urinary retention; a prospective, placebo-controlled trial. BJU Int 2001;88(Suppl 1):77
   PubMed Web of Science ®Google Scholar
• Kim HL, Kim JC, Benson DA, et al. Results of treatment with tamsulosin in men with acute urinary retention. Tech Urol 2001;7:256-60
   PubMedGoogle Scholar
• Lucas MG, Stephenson TP, Nargund V. Tamsulosin in the management of patients in acute urinary retention from benign prostatic hyperplasia. BJU Int 2005;95:354-7
   PubMed Web of Science ®Google Scholar
• Abrams P, Amarenco G, Bakke A, et al. Tamsulosin: efficacy and safety in patients with neurogenic lower urinary tract dysfunction due to suprasacral spinal cord injury. J Urol 2003;170:1242-51
   PubMed Web of Science ®Google Scholar
• McConnell JD, Roehrborn CG, Bautista OM, et al. The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia. N Engl J Med 2003;349:2387-98
   PubMed Web of Science ®Google Scholar
• Kaplan SA, McConnell JD, Roehrborn CG, et al. Combination therapy with doxazosin and finasteride for benign prostatic hyperplasia in patients with lower urinary tract symptoms and a baseline total prostate volume of 25 ml or greater. J Urol 2006;175:217-20
   PubMed Web of Science ®Google Scholar
• Siami P, Roehrborn CG, Barkin J, et al. Combination therapy with dutasteride and tamsulosin in men with moderate-to-severe benign prostatic hyperplasia and prostate enlargement: the CombAT (Combination of Avodart and Tamsulosin) trial rationale and study design. Contemp Clin Trials 2007;28:770-9
   PubMed Web of Science ®Google Scholar
• Kaplan SA, Gonzalez RR, Te AE. Combination of Alfuzosin and Sildenafil is superior to monotherapy in treating lower urinary tract symptoms and erectile dysfunction. Eur Urol 2007;51:1717-23
   PubMed Web of Science ®Google Scholar
• Kaplan SA, Roehrborn CG, Rovner ES, et al. Tolterodine and tamsulosin for treatment of men with lower urinary tract symptoms and overactive bladder: a randomized controlled trial. JAMA 2006;296:2319-28
   PubMed Web of Science ®Google Scholar